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Biglycan is an extracellular matrix component of many parts of the skeleton
including bone, cartilage, tendon, teeth and muscle. Biglycan is predomi-
nantly expressed as a proteoglycan, but a mature form lacking GAG side
chains (‘nonglycanated’) has recently been shown to have specific functions in
muscle, synapses and Wnt signaling in bone. The biglycan gene is on the X
(and not Y) chromosome and is dysregulated in Turner (XO) and Kleinfelter’s
Syndromes (supernumery X) diseases, characterized by short and tall stature
respectively. Biglycan deficient mice have shorter bones as well as lower bone
mass (ostepenia/osteoporosis) [1], another notable feature observed in Turner
Syndrome. The mechanisms underlying the thinner and weaker bones
produced without biglycan have been studied in detail and point to the fact
that biglycan modulates multiple pathways critical to skeletal metabolism.
While biglycan is not needed for development of the musculoskeletal
system, it is required for the maintenance of its integrity. In adult bone
turnover is regulated by a fine balance between bone formation by osteo-
blasts and bone resorption by osteoclasts. In the absence of biglycan, there is
decreased bone formation due to defects in the maturation of osteogenic
precursors that form bone [2]. Bone Morphogenic Protein 2/4 (BMP-2/4), a
well-known inducer of bone formation, is currently being used therapeuti-
cally to aid bone repair. Bone-derived cells depleted of biglycan have less
BMP-2/4 binding and subsequently less osteogenic differentiation. It is
logical to conclude that biglycan could be a prime candidate to enhance
BMP-2/4 function in situations where it is commonly used such as in bone
regeneration and repair after fracture or trauma.
Mice lacking biglycan also display pathologies typically associated with
skeletal aging. Specifically, by three months of age, hallmark signs of
osteoarthritis (OA) are evident in the mutant mice, including fissures, cell
clustering and loss of the smooth articular cartilage surface on the joints. The
OA is detected in all weight bearing joints as well as in the temporoman-
dibular joint of the jaw. The effects of biglycan loss are exacerbated
by depletion of the related small leucine-rich proteoglycan fibromodulin
(Bgn/0; Fmod/ DKO). Molecular studies point to the abnormal seques-
tration of the potent growth factor TGF-b in the combined absence of
biglycan and fibromodulin causing it to be ‘unleashed’ and subsequently
overactive. The uncontrolled stimulation of TGF-b in this context
leads to hyper-proliferation, premature differentiation of cartilage derived
cells, MMP induction and, ultimately, loss of the condyle tissue integrity
[3].
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modulating the extracellular niche. This function was
demonstrated in ECM-rich tendon tissue that harbors a
cell population with stem cell features including clono-
genicity, multipotency and regenerative capabilities [4].
The combined removal of biglycan and fibromodulin
caused tendon stem/progenitor cells to be hypersensitive
to BMP-2: instead of differentiating into tendon, these
progenitors form multiple ectopic bones within the ten-
dons that affect the gait of the mice. Biglycan also controls
other factors critical to bone in addition to TGF-b and
BMP-2/4. In humans, a mutation in the extracellular
domain of the key Wnt signaling molecule LRP-6
(R611C) causes elevated cholesterol and osteopenia.
Notably, exogenous application of non-glycanated bigly-
can repaired the defective Wnt signaling in cells expres-
sing mutant LRP-6 [5]. Thus, biglycan could potentially
ameliorate pathologies caused by defective Wnt sig-
naling. Taken together these findings underscore the
importance of biglycan in modulating several key growth
factor-mediated signaling pathways that regulate skeletal
tissue architecture and function.
Biglycan also plays a role in organizing membrane archi-
tecture and function in muscle and at synapses. Muscle
membranes are highly specialized to transmit force, pro-
tect the cell from contraction-induced damage and
orchestrate signaling pathways required for normal func-
tion. The dystrophin-membrane and utrophin-membrane
glycoprotein complexes (DGC and UGC, respectively)
link the cytoskeleton to the extracellular matrix and serve
as a scaffold for signaling molecules in adult (DGC) and
immature (UGC) muscle. Biglycan binds to three shared
components of these complexes: the extracellular per-
ipheral membrane protein a-dystroglycan and the trans-
membrane proteins a-sarcoglycan and g-sarcoglycan
[6,7]. Genetic studies show that biglycan regulates the
expression of utrophin, the two sarcoglycans and an
intracellular membrane-associated signaling complex
comprised of dystrobrevin, syntrophins and nNOS
(neuronal nitric oxide synthase) in immature muscle
[8]. Notably, dosing mice with recombinant non-glyca-
nated biglycan (rNG-BGN) can restore the expression of
several of these components to the membrane [8].
The role of biglycan in binding and regulating several
components of DGC and UGC, coupled with the ability
to deliver rNG-BGN systemically, suggested that biglycan
could be a therapeutic for Duchenne Muscular Dystrophy
(DMD). DMD is the most common form of muscular
dystrophy and results from mutations in dystrophin – a
large intracellular protein that links the actin cytoskeleton
to the membrane and anchors the DGC. Notably, utrophin
upregulation can compensate for dystrophin loss in mouse
models of DMD (mdx; Davies). Systemically delivered
rNG-BGN recruits utrophin to the membrane and
improves muscle health and function in mdx mice [9].www.sciencedirect.com The efficacy of the non-glycanated form (i.e. lacking GAG
side chains) in this therapeutic approach is most probably
based on two reasons. First, this form can be readily
manufactured in a homogeneous form. Second, biglycan
proteoglycan (PG) but not non-glycanated (core) is proin-
flammatory [10]. A non-glycanated form of biglycan is
currently in preclinical development for DMD.
Biglycan is also important for synapse stabilization [11]. In
biglycan-deficient mice, neuromuscular junctions form
normally but then they become unstable about three
weeks after birth. The mechanism of biglycan action at
the synapses is likely to involve MuSK, a receptor tyro-
sine kinase that is the master regulator of synapse differ-
entiation and maintenance. Biglycan binds to MuSK and
regulates its expression in vivo. Notably, synaptic loss is
one of the earliest abnormalities observed in almost all
neurodegenerative diseases, including ALS (amyotrophic
lateral sclerosis) and SMA (spinal muscular atrophy).
Treatments that promote neuromuscular junction
stability could prolong function and potentially survival
in these devastating motor neuron diseases.
In summary, biglycan plays important roles in the mus-
culoskeletal system. The fact that non-glycanated forms
of biglycan are effective in ameliorating muscle defects
and that it can be administered systemically makes it
particularly amenable for tissue and cell therapy. Taken
together, it is reasonable to conclude that biglycan holds
promise as a novel therapeutic for numerous musculos-
keletal diseases including low bone mass, osteoarthritis,
ectopic bone formation and muscular dystrophy.
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